Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-ZHER2:41071
- Development stage
- Unknown
- Lead developer
- Affibody
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
99mTc-ZHER2:41071 is a second-generation affibody molecule labeled with the radionuclide technetium-99m, designed for molecular imaging of human epidermal growth factor receptor 2 (HER2) expression in tumors using single photon emission computed tomography (SPECT). The ZHER2:41071 scaffold has been engineered to improve stability, hydrophilicity, and storage properties compared to earlier generations. It binds specifically and with high affinity to HER2-expressing cells (affinity ~58 pM), enabling non-invasive visualization and quantification of HER2 status in cancers such as breast cancer. Preclinical and phase I clinical studies have shown that 99mTc-ZHER2:41071 provides excellent tumor-to-blood ratios, low renal uptake compared to previous probes, favorable dosimetry, and safety in humans. Its primary use is as a diagnostic radiopharmaceutical for stratifying patients who may benefit from HER2-targeted therapies[1][4][6].
- Other names
- technetium-99m-labeled ZHER2:41071Tc-99m-ZHER2:41071
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 99mTc-ZHER2:41071.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-ZHER2:41071.